QuantWave Hits the Mark: GSK PLC Price Target Forecast Achieves 13.72% Profit
October 1, 2025
QuantWave Hits Bullseye with GSK PLC Forecast, Yielding 21.25% Profit
October 1, 2025
QuantWave's Forecast Delivers 12.77% Profit as GSK PLC Hits Price Target
October 1, 2025
QuantWave Achieves Stellar 14.46% Profit Forecast for GSK PLC
October 1, 2025
QuantWave Achieves 10.45% Profit Target Forecast for GSK PLC
October 1, 2025
Price Target Forecast Success: GSK PLC Hits 13.2% Profit Goal
October 1, 2025
GSK PLC: Combination Vaccines Market to See Significant Growth in Coming Years
January 2, 2025
GSK PLC: Combination Vaccines Market shows Promising Growth Opportunities
January 2, 2025
GSK GSK Collaborates with University of Oxford for Cancer Vaccine Research
February 4, 2025
Exciting Potential Ahead for GSK PLC as FDA Accepts Review of Innovative Shingrix Syringe
January 12, 2025
GSK PLC reports strong growth in specialty medicines in Q3 2024 earnings call
November 6, 2024
Investor opinions & comments
To leave a comment, you need to Login or Register.
KatherineSanchez
February 10, 2025 at 10:43
While GSK's revenue exceeded expectations, it's important to consider if this growth is sustainable. The success of their HIV and cancer drugs might not be consistent in the future
MoneyMabel
February 9, 2025 at 03:25
I'm definitely considering buying GSK stocks based on these positive results. Their revenue exceeding expectations is a promising sign for the company
DividendDylan
February 8, 2025 at 17:22
The 2 billion dollar share buyback program sounds like a smart move by GSK. It shows their confidence in their future performance
NatalieBaker
February 8, 2025 at 14:53
GSK's optimistic outlook for their vaccine portfolio is encouraging. Vaccines play a crucial role in public health, and GSK's commitment to improving and expanding their portfolio is commendable
WealthyWanda
February 8, 2025 at 10:06
It's great to see GSK's revenue exceeding expectations. This demonstrates their strong market position and potential for future growth
LoganWard
February 7, 2025 at 23:09
GSK's strong performance in 2024 is impressive. Their success in the HIV and cancer drug market is a testament to their innovation and ability to meet healthcare needs
MoneyMonique
February 7, 2025 at 15:55
This is great news for GSK! I'm excited to see how their HIV and cancer drugs continue to perform and drive their long-term growth
MarketMason
February 7, 2025 at 06:41
I'm not sure if GSK can sustain this level of growth in the long term. The pharmaceutical industry is highly competitive, and it's difficult to predict how market dynamics will change
SaraBrown
February 7, 2025 at 06:00
I'm skeptical about GSK's vaccine portfolio. With the challenges faced by the global vaccine market, it's uncertain how successful GSK will be in this area